From Cold to Hot: Perceptions of the Use and Impact of QSP in Immuno-oncology – A Survey of the Community and Stakeholders
Vincent Lemaire, Ph.D.; Fei Hua, Ph.D.
Distinguished Scientist Modeling and Simulation, Genentech, South San Francisco, CA; VP, Head of Modeling and Simulation Services, Applied BioMath Concord, MA
Webinar Recording
Immuno-oncology (IO) is a fast-expanding field due to recent successes in treating cancer. It is also a challenging field where therapeutics have to leverage the complex interactions between a tumor and the immune system. Approaches that can make sense of this complexity are required to better inform IO therapy research and development. Quantitative systems pharmacology (QSP) modeling has the potential to address some of the challenges in the IO field, by representing biological mechanisms of disease and the mode of action of drugs with mathematical equations. To assess the perspectives of the community on the impact of QSP modeling in IO drug development and to understand current applications and challenges, the IO QSP working group-under the QSP Special Interest Group (SIG) of the International Society of Pharmacometrics (ISoP)-conducted a survey among QSP modelers, non-QSP modelers, and non-modeling IO program stakeholders. The survey results are presented here with discussions on how to address some of the key findings.